Piper Sandler analyst David Westenberg maintained a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $30.00. The company’s shares closed yesterday at $19.44.
Westenberg covers the Healthcare sector, focusing on stocks such as Zoetis, Natera, and Exact Sciences. According to TipRanks, Westenberg has an average return of -1.4% and a 41.98% success rate on recommended stocks.
Guardant Health has an analyst consensus of Strong Buy, with a price target consensus of $37.22.
GH market cap is currently $2.37B and has a P/E ratio of -4.96.
Based on the recent corporate insider activity of 97 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GH in relation to earlier this year. Earlier this month, Helmy Eltoukhy, the Co- CEO of GH bought 200,000.00 shares for a total of $836,000.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Guardant Health (GH) Company Description:
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
Read More on GH:
- Guardant Health Earnings Report: Is it a Beat?
- Guardant Health price target lowered to $30 from $45 at Canaccord
- Guardant Health assumed with a Buy at Craig-Hallum
- FDA Advisory Panel review of Guardant Health Shield Blood Test on May 23
- Guardant Health to present data on epigenomics at 2024 AACR meeting
